US pharma manufacturer enters Chapter 11 after failed takeover and FDA warnings
Aiming to seek an in-court sale of its business, international pharma company Akorn and its US subsidiaries have entered Chapter 11 following a failed takeover and multiple actions and warnings from the US’s Federal Drug Administration.
To read more
Subscribe to Global Restructuring Review
Subscribe & start reading now!
GRR is a daily information service providing cross-border insolvency and restructuring news, features and events.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10